ZOLDRIA is a drug containing zoledronic acid that suppresses bone resorption and increases bone density. It is used for the treatment of osteoporosis in postmenopausal women and men at risk of fractures. The drug is also used for treating hypercalcemia associated with cancer, reducing calcium levels in the blood and preventing complications.
The product is used for:
Osteoporosis in postmenopausal women
Osteoporosis in men
Prevention of fractures in osteoporosis patients
Hypercalcemia related to cancer
ZOLDRIA is administered intravenously at a dose of 4 mg once a year (for osteoporosis treatment) or as directed by the doctor. For hypercalcemia treatment, the dosage and schedule may be adjusted based on the patient's condition. The injection is given slowly, and the patient should be monitored by a doctor for 30 minutes after administration.
Contraindications:
Hypersensitivity to the components of the product
Severe kidney disease
Pregnancy and breastfeeding
Lactation
Side Effects:
Flu-like symptoms (chills, fever, muscle pain)
Bone and joint pain
Kidney dysfunction (in rare cases)
Nausea, dyspepsia
Allergic reactions (rash, itching)
